APA (7th ed.) Citation

VM, M., FV, M., GA, Y., ES, K., AP, S., IV, B., . . . EN, I. (2018). First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients. Clinical drug investigation, 38(6), 553. https://doi.org/10.1007/s40261-018-0629-1

Chicago Style (17th ed.) Citation

VM, Moiseyenko, et al. "First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients." Clinical Drug Investigation 38, no. 6 (2018): 553. https://doi.org/10.1007/s40261-018-0629-1.

MLA (9th ed.) Citation

VM, Moiseyenko, et al. "First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients." Clinical Drug Investigation, vol. 38, no. 6, 2018, p. 553, https://doi.org/10.1007/s40261-018-0629-1.